(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cutaneous T-Cell Lymphoma pipeline constitutes 30+ key companies continuously working towards developing 35+ Cutaneous T-Cell Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading →

Intravascular Ultrasound Market Insights, Competitive Landscape, and Market Forecast – 2034” report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers.   As per DelveInsight’s assessment, Factors such as an aging population, rising obesity … Continue reading →

The Key Dilated Cardiomyopathy Companies in the market include – Bristol Myers Squibb, Berlin Cures, Cumberland Pharmaceuticals, Vericel Corporation, Corimmun GmbH, Pfizer, Constant Therapeutics LLC, Cumberland Pharmaceuticals, and others.   DelveInsight’s “Dilated Cardiomyopathy Market Insights, Epidemiology, and Market Forecast-2034″ report … Continue reading →

Neurovascular Devices Market Insights, Competitive Landscape, and Market Forecast – 2034” report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers.   As per DelveInsight’s assessment, The neurovascular devices market is mainly propelled by … Continue reading →

TECVAYLI + DARZALEX FASPRO FDA Approval Johnson & Johnson (NYSE: JNJ)’s Phase 3 MajesTEC-3 data show an 83% reduction in risk of disease progression or death, with 83.3% of patients alive at three years reshaping the multiple myeloma treatment paradigm … Continue reading →

FDA Orphan Drug Designation for GENFIT’s G1090N With no approved therapy for Acute-on-Chronic Liver Failure (ACLF) and approximately 62K cases recorded across major markets, this FDA designation of GENFIT’s G1090N signals an accelerating race to address one of hepatology’s most … Continue reading →

FDA Grants Priority Review to ENHERTU in Post-Neoadjuvant HER2-Positive Early Breast Cancer Phase III DESTINY-Breast05 data shows a 53% reduction in invasive disease recurrence or death vs. T-DM1, redefining the standard of care for nearly 16,000 annual post-neoadjuvant patients in … Continue reading →

FDA Accepts NDA for Rusfertide and Grants Priority Review in Polycythemia Vera Takeda and Protagonist Therapeutics’ first-in-class hepcidin mimetic moves closer to market as FDA sets Q3 2026 PDUFA date; DelveInsight’s Polycythemia Vera Market Report tracks the full competitive and … Continue reading →